Abstract-The chromosome 9p21 (Chr9p21) locus was discovered in 2007 by independent genome-wide association studies for coronary artery disease. Since then, the locus has been replicated numerous times and can be considered the most robust genetic marker of coronary artery disease today. Subsequent work has shown associations of Chr9p21 with a number of additional cardiovascular disease traits, such as carotid artery plaque, stroke, aneurysms, peripheral artery disease, heart failure, and cardiovascular mortality, suggesting a more general role in vascular pathology. Importantly, Chr9p21 lacks associations with common cardiovascular risk factors, such as lipids and hypertension, indicating that the locus exerts its effect through a completely novel mechanism. One of the challenges is that the core haplotype block at Chr9p21 resides in a region of the genome devoid of protein-coding genes. 
T he identification of the chromosome 9p21 (Chr9p21) locus of coronary artery disease (CAD) has been a landmark discovery in cardiovascular genetics. Like many important advances in science, it was fostered by an advancement of technology, in this case the availability of dense gene arrays. These arrays permitted the investigation of genetic variation at a genome-wide level with reasonable coverage. This allowed hypothesis-free approaches to investigate genetic components of disease using genome-wide association study (GWAS) designs. Until today, GWASs have been extremely successful in identifying novel genetic factors of multiple disease traits (reviewed in 1, 2 ) . It is thus not surprising that the Chr9p21 locus was discovered in the first surge of GWASs for CAD in 2007 and published simultaneously by 4 independent groups only a few weeks apart. [3] [4] [5] [6] Today, Chr9p21 represents the most replicated marker of CAD and myocardial infarction (MI). [7] [8] [9] The Chr9p21 locus harbors a haplotype block containing multiple single-nucleotide polymorphisms in tight linkage disequilibrium, spanning a region of approximately 50 kb of DNA sequence (Figure 1 ). 4, 8, 10 The risk allele is common with an allele frequency of 50%. The conferred increase of CAD risk is Ϸ30% and Ϸ60% for carriers of 1 and 2 alleles, respectively. Interestingly, the risk is independent of conventional risk factors of CAD, such as hypertension or hyperlipidemia. [3] [4] [5] [6] In this context, it is also important to recognize that the Chr9p21 locus acts independently of a close-by locus of diabetes mellitus. 11 The latter is located in the adjacent haplotype block on chromosome 9p21, more distal to the CAD region ( Figure 1 ). 12 Taken together, these results suggest that Chr9p21 might affect atherosclerosis through a completely novel mechanism.
Another intriguing finding was that the genomic region comprising the Chr9p21 CAD haplotype is a "gene desert," devoid of annotated protein-coding genes ( Figure 1 ). The closest protein-coding genes are located a few kilobases proximal of the CAD region. These genes are the 2 cyclindependent kinase inhibitors, CDKN2B (encoding p15 INK4b ) and CDKN2A (encoding p16 INK4a and p14 ARF ) as well as methylthioadenosine phosphorylase (MTAP). CDKN2A and CDKN2B are involved in cell cycle control, and MTAP plays a role in the salvage of adenine and methionine, which is important for smooth muscle cell proliferation. Because these mechanisms are known to play a role in atherogenesis, CDKN2B, CDKN2A, and MTAP were considered prime candidate genes at the locus. However, the picture appears to be more complex: although there are no protein-coding genes in the immediate CAD haplotype block, the region contains a long intergenic noncoding RNA, designated antisense noncoding RNA in the INK4 locus (ANRIL) (Figure 1) . A synonym is CDKN2BAS (CDKN2B antisense RNA). 13 Recent studies have shown that ANRIL expression is regulated by Chr9p21 and might thus constitute a key factor for understanding the pathophysiology at the locus.
This review focuses on potential mechanisms and the clinical relevance underlying the Chr9p21 locus of CAD. We summarize major clinical and experimental studies that have been conducted during the 4 years following its discovery and discuss the emerging view of the pathophysiology underlying Chr9p21.
Association of Chr9p21 With Cardiovascular Disease Coronary Artery Disease
The initial discovery of Chr9p21 was made in CAD and MI cohorts of predominantly European descent. [3] [4] [5] [6] The locus has now been replicated in many ethnicities, such as Korean, 14 Japanese, 15 Chinese, 16 Pakistani, 17 and US Hispanic 18 populations. Although the association of 9p21 with CAD risk is consistent among these populations, the haplotype structure of this region and relationship to CAD differs for African blacks. 4, 18, 19 A recent metaanalysis of 35 872 cases and 95 837 controls found that the effect of Chr9p21 on CAD was dependent on the age at disease onset: individuals aged 55 years or younger had an odds ratio ( 9 implying a stronger effect of Chr9p21 at earlier age of CAD onset (Table 1) . 9 Importantly, the association of Chr9p21 with CAD has been reported not only in case-control designs but also in prospective studies with hazard ratios of 1.2, 20,21 1.25, 22 and 1.38 23 per risk allele. Recent work has also addressed the issue of at what stages of CAD development Chr9p21 might be important. These studies were performed within CAD populations (as opposed to comparisons between CAD and non-CAD populations) that underwent coronary angiography at different time points allowing follow-up. 24 -26 Individuals with 1 or 2 copies of the Chr9p21 risk allele had more severe CAD 24, 25 and progressed faster compared with individuals with 0 copies. 25, 26 Importantly, Chr9p21 did not predispose to MI in patients with preexisting CAD 24 or reoccurrence of MI in patients with early MI. 26 These studies corroborated earlier results showing that Chr9p21 was not associated with incident MI, although it did predict CAD diagnosis (Table 1) . 27 Taken together, current data provide the first evidence that Chr9p21 is important for promoting atherosclerosis leading to CAD, whereas it might not be relevant for triggering MI. 28 This concept does not contradict the frequently replicated association of Chr9p21 with MI 8 because the latter associations were reported when comparing MI patients with healthy controls, and MI is almost always preceded by CAD. It will be important to see these findings replicated in the future.
Carotid Artery Disease
Atherosclerotic burden in the carotid arteries is usually assessed using ultrasound. The distance between the luminal 
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side and the echogenic adventitia is defined as carotid intima-media thickness. By definition, thickening Ͼ1.0 mm or protrusion is considered as atherosclerotic plaque. 29 A strong association of Chr9p21 has been noted for plaque in the carotid artery (OR 1.31-1.46). 30, 31 Chr9p21 was associated not only with prevalent carotid plaque but also with disease progression (OR 1.73-1.87). 31 Surprisingly, there was no significant association of Chr9p21 with carotid intimamedia thickness (Table 1) . 30, 32 This was of interest because it is commonly believed that intima-media thickening might constitute a precursor to atherosclerotic plaque formation. Taken together, it appears that Chr9p21 is less important for initiating early stages of (subclinical) atherosclerosis but rather for the events promoting lesion formation. This view is supported by the lack of association of Chr9p21 with early changes in brachial flow-mediated dilatation 32 as a marker of early preclinical atherosclerosis even though the latter data have been disputed. 33
Stroke
The identification of Chr9p21 in CAD stimulated a number of studies investigating a potential association with stroke as a cardiovascular-related phenotype. These studies yielded conflicting results. Although some studies have shown a link between Chr9p21 and ischemic stroke, 21,34 -37 others (predominantly GWASs) failed to identify this association. 38 -40 This issue was addressed in a recent metaanalysis of 8 ischemic stroke studies. 41 This analysis confirmed that Chr9p21 is a risk factor for ischemic stroke even though the OR was only Ϸ1.1 and thus lower than for CAD. Subtype analysis revealed a substantial increase in the effect of the Chr9p21 association for large artery stroke (OR Ϸ1.2), achieving an effect size similar to that observed for CAD (Table 1) . 41 Thus, previous inconsistent findings might have been related to subtype specificity, and it now appears safe to conclude that Chr9p21 is indeed associated with ischemic stroke.
Aneurysms
Shortly after publication of the association of Chr9p21 with CAD, it was demonstrated that the same variants were also associated with the presence of aneurysms in the abdominal aorta and intracranial arteries. 38 The initial study was conducted in 2836 cases and 16 732 controls of European descent. ORs were 1.31 for abdominal aortic aneurysm and 1.29 for intracranial aneurysm (Table 1) . 38 Results have subsequently been confirmed in a metaanalysis. 42 With respect to intracranial aneurysms, Nakaoka et al pointed out that the strength of the Chr9p21 association varied by anatomic location. These authors found that the association was stronger for aneurysms in the posterior communicating artery and the posterior circulation than in the anterior circulation. 43 It is commonly believed that the formation of aneurysms is only in part dependent on atherosclerosis. 44 Therefore, the association of Chr9p21 with aneurysms suggests that Chr9p21 has a broader role in vascular pathology, implicating altered vascular structural integrity as a causal mechanism.
Peripheral Artery Disease
In their study investigating effects of Chr9p21 on aneurysms, Helgadottir et al also reported an association with peripheral artery disease (OR 1.14; Table 1 ). 38 Notably, the association disappeared when removing those individuals with histories of MI, suggesting a lack of independent effect on the peripheral arteries. 38 A recent study in older populations and work by our own group confirmed that the risk allele at Chr9p21 was indeed associated with increased prevalence of peripheral artery disease. 30, 45 In contrast to the study by Helgadottir et al, 38 work by Cluett et al showed that the association of Chr9p21 with peripheral artery disease was independent of the presence of diagnosed MI and atherosclerotic risk factors. 45 These data add evidence for a broader role of Chr9p21 in vascular disease.
Heart Failure
Heart failure is a common consequence of CAD. It was therefore tested whether Chr9p21 was associated with incident heart failure in the Atherosclerosis Risk in Communities study. 46 Indeed, there was a significant association of Chr9p21 with hospitalization or death due to heart failure ( Table 1) , and the association seemed independent of the established link between Chr9p21 and clinical CAD. However, an impact on subclinical CAD leading to heart failure could not be eliminated. 46 
Cardiovascular Mortality
A recent analysis in the Elderly-Iowa cohort pointed out that the Chr9p21 risk allele was associated with excess mortality in elderly subjects (hazard ratio 1.19; Ͼ71 years), mainly attributed to CAD mortality. 47 This observation is remarkable, because of the presumed weaker effect of Chr9p21 in older populations (Table 1) . 9 A metaanalysis in 6 prospective cohort studies showed that Chr9p21 was also associated with sudden and arrhythmic cardiac death, and controlling for cardiovascular and lifestyle risk factors strengthened this relationship (OR 1.29). 48 Another study demonstrated that Chr9p21 was independently associated with all-cause mortality after primary coronary artery bypass surgery even after adjusting for other clinical predictors of mortality in a Cox proportional hazards model (hazard ratio: 1.7). 49 Addition of Chr9p21 to the EuroSCORE also significantly improved model prediction for mortality. 49 The latter associations are probably not entirely explained by atherosclerotic alteration of the vessels as the common causal mechanism, corroborating the existence of additional mechanisms of vascular disease formation underlying the locus.
CAD-Related Phenotypes
To elucidate potential underlying mechanisms, a number of studies have investigated the relation of Chr9p21 with phenotypes that are possibly related to CAD. Robust positive associations have been detected for only 2 such conditions, namely increased platelet reactivity as determined by whole blood impedance aggregometry in response to collagen 50 and periodontitis. 51, 52 The study by Musunuru et al 50 is of particular interest because platelets are well-known contributors to atherogenesis and vascular repair. It has been suggested that
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the Musunuru et al study might point to a shared platelet signaling pathway downstream of the 2 major pathways of platelet activation by epinephrine and collagen. 53 The other CAD-related phenotype associated with Chr9p21 was periodontitis. 51, 52 An association between CAD and periodontitis had been established in previous work and was the rationale for these studies. 54 Cosegregation of CAD and periodontitis supports that the two diseases have common underlying mechanisms that are both modulated by Chr9p21. This view is corroborated by comparable patterns of gene expression underlying both pathologies. 7, 30, 55 Other studies have investigated the interaction of Chr9p21 with CAD risk factors in the development of CAD. One such study revealed that the CAD risk associated with the Chr9p21 variant was increased in the patients with type 2 diabetes and poor glycemic control. 56 This suggested a potential interaction between the Chr9p21 CAD haplotype and diabetes mellitus in the development of CAD. These data were supported by a recent study that showed that the Chr9p21 risk allele conferred a magnified risk of early onset and more CAD in Chinese diabetic patients compared with nondiabetic patients. 57 Unfortunately, only few published negative reports of Chr9p21 associations of with intermediate phenotypes have been reported, potentially because of negative publication bias. Considering the current poor understanding of the pathophysiology of Chr9p21, the latter might be equally important, because such work would exclude potential mechanisms. For example, 1 such study showed that there was no evidence of reduced endothelial progenitor cell numbers or colony formation units in carriers of the Chr9p21 risk variant. 58 
GWASs of Noncardiovascular Phenotypes and Chr9p21
A number of GWASs for other disease phenotypes, such as for breast cancer, 59 basal cell carcinoma, 60 glioma, 61,62 nasopharyngeal carcinoma, 63 optic disk parameters, 64 and glaucoma, 65 also showed signals of association at Chr9p21. Interestingly, these hits all mapped closer to the INK/ARF locus outside the core Ϸ50-kb cardiovascular haplotype block, which appears to be relatively specific to vascular disease ( Figure 1 ). One exception is endometriosis, which had its top signal of association in the same haplotype block. 66 Even though this would suggest a functional link, the underlying mechanism is currently unknown. Other GWASs for amyotrophic lateral sclerosis, 67 cutaneous nevi, 68 and melanoma 69 showed significant associations at Chr9p21, but the top hits were completely outside the cardiovascular risk region and the INK/ARF locus plotted in Figure 1 , speaking against a functional relationship.
Mechanisms Underlying Chr9p21
The
INK4/ARF Locus
The core CAD region at Chr9p21 is only slightly distal to the INK4/ARF locus (Figure 1) . Loss of the INK4/ARF locus impairs cell-cycle control and is one of the most frequent events in the development of cancer. 70 
INK4/ARF encodes 2 cyclin-dependent kinase inhibitors, p15
INK4b and p16 INK4a , as well as p14 ARF , an unrelated regulator protein of the p53 pathway. 71 These proteins are well-established tumor suppressors and somatic mutations impairing gene function are commonly observed in human cancers. 70 Whereas p15 INK4b is transcribed from its own independent gene (CDKN2B), p16 INK4a and p14 ARF share the second and third exons of CDKN2A (Figure 1) . p16 INK4a and p14 ARF use independent promoters and p14 ARF splices exon 2 in an alternative reading frame (hence the name ARF). 71, 72 p14 ARF activates p53, resulting in either cell-cycle arrest or apoptosis. 73, 74 In contrast, p15
INK4b and p16 INK4a have similar functions by specifically binding to cyclin-dependent kinase inhibitors 4 and 6. These inhibitors prevent phosphorylation of retinoblastoma family proteins, resulting in G 1 phase arrest and blockage of cell proliferation. 72 The locus contains a fourth gene, methylthioadenosine phosphorylase (MTAP), which is located more proximally but has annotated exons overlapping the INK4/ARF locus. 75 MTAP catalyzes the phosphorylation of 5Јmethyladenosine in the polyamine pathway, which has also been associated with cell growth and death. 76 Because cell proliferation and apoptosis play an important role in atherogenesis, it was self-evident that genes at the INK4/ARF locus might constitute candidates for atherosclerosis. Studies by Folkersen et al 77 and our group 78 showed robust expression of CDKN2A, CDKN2B, and MTAP in normal and atherosclerotic coronary arteries. However, expression levels of these genes in vascular tissue showed no clear association with the Chr9p21 genotype (Figure 2 ), speaking against a role of vascular tissue expression of these genes in determining atherosclerosis susceptibility. 77, 78 Various studies have also investigated the association of CDKN2A, CDKN2B, and MTAP expression with Chr9p21 in peripheral blood cells, but the majority of these studies have shown no effects (Figure 2 ), corroborating the lack of effect seen in vascular tissues. 30,79 -82 Currently 2 of the INK4/ARF genes, namely p19 ARF (corresponding to human p14 ARF ) and p16 INK4a , have been specifically tested for their role in atherogenesis in knockout mouse models. 83, 84 Gonzalez-Navarro et al used a mouse with whole-body deletion of p19 ARF , augmenting aortic atherosclerosis on the Apoe-null background. 83 Ldlr Ϫ/Ϫ mice transplanted with bone marrow with heterozygous deficiency of both p19 ARF and p16 INK4a also exhibited accelerated atherosclerosis. 84 As a caveat, it is important to note that significant differences exist between the regulation of human p14 ARF and its mouse ortholog p19 ARF . Most notably, whereas mouse p19 ARF is upregulated during Ras-induced senescence, human p14 ARF is not (reviewed in 85 ). In another publication, a 70-kb noncoding interval in the mouse adjacent to the INK4/ARF locus was deleted. 86 This region was thought to be orthologous to the human risk haplotype and contains a long RNA, although the percentage of interspecies conservation of this region is only 50%, and no clear ortholog of ANRIL exists in the mouse. 86 In this mouse model, a significant reduction of CDKN2B and CDKN2A expression levels and an increase in cell proliferation was found. 86 However, no significant effect on atherosclerotic lesion formation was seen, raising doubts about the suitability of this model for studying Chr9p21 effects on atherosclerosis.
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Taken together, studies of the INK/ARF locus in mice and men speak in favor of a possible role of the INK/ARF protein-coding genes in atherosclerosis. However, these effects are likely independent of Chr9p21, because there is currently no evidence for a regulation of these genes by Chr9p21 in human tissues, except for 1 study in T cells. 80 
Association of the Long Intergenic Noncoding RNA ANRIL With the Chr9p21 Genotype
ANRIL (CDKN2BAS) is a long non-coding RNA which is transcribed from the INK/ARF locus. It has been first described a few months prior and unrelated to the discovery of Chr9p21 as a risk locus for CAD. 13 The name ANRIL (antisense noncoding RNA in the INK4 locus) is derived from its direction of transcription antisense to CDKN2A and CDKN2B, whereas the synonym CDKN2BAS (CDKN2B antisense RNA) refers to its physical position spanning p15
INK4b in antisense direction. Because of its position within the Chr9p21 CAD core haplotype block, ANRIL is currently considered a prime candidate for atherosclerosis at the Chr9p21 locus. ANRIL is expressed in tissues and cell types that are affected by atherosclerosis. 30, 77, 78, 82 Until now, multiple linear as well as circular isoforms have been identified. 77, 87 These findings have stimulated a number of studies investigating ANRIL's association with the Chr9p21 genotype ( Figure 2 ). The majority of these studies show robust associations of ANRIL expression with the Chr9p21 genotype, even though the directions of effects are inconsistent. 30,79 -81,87 A potential reason is that these studies have been performed in different tissues (predominantly preparations of peripheral blood cells) and used quantitative reverse transcriptionpolymerase chain reaction assays spanning different exons of ANRIL (Figure 2) . A study from our group that has been performed in blood mononuclear cells from 1098 patients with and without CAD revealed that increased expression of ANRIL transcripts containing exon transitions 1 to 5 and 18 to 19, formerly termed ANRIL EU741058 and NR_003529, respectively, was highly significantly associated with the Chr9p21 risk allele. 30 This finding was replicated in whole blood from patients of the same cohort. Moreover, increased ANRIL was also associated with increased atherosclerosis. 30 These results are concordant with recent findings of Harismendy et al showing that Chr9p21 CAD-risk alleles at rs10811656 and rs10757278 disrupt a binding site for STAT1 that in turn inhibits ANRIL expression in lymphoblastoid cell lines homozygous for the protective Chr9p21 haplotype. 88 Resequencing of the Chr9p21 region and imputation of the identified variants into MI cohorts identified additional single-nucleotide polymorphisms in tight LD with equivalent evidence of MI association as compared with single-nucleo- 
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Recent Studies of the Human Chromosome 9p21 Locustide polymorphisms disrupting the STAT1 site, 10 suggesting the possibility of additional functional variants. 91, 92 Two major PRCs, namely PRC1 and PRC2 have been described. PRC1 recruitment results in the ubiquitinylation of histone H2A on lysine 119, which is thought to be important for the maintenance of transcriptional repression. 93 In contrast, PRC2 appears to be involved in establishing repressive chromatin states involving trimethylation of the lysine 27 residue on histone 3 (H3K27me3). 93 Yap et al showed that ANRIL associates with the Polycomb-group protein CBX7, which is part of the PRC1 complex, and together they repress expression of p16 INK4a . 92 Knockdown of ANRIL RNA expression was associated with increased p16
Potential Mechanism of ANRIL
INK4a expression, decreased H3K27me3 methylation, and CBX7 binding to the p16
INK4a locus, whereas expression of p15
INK4b remained unchanged. 92 Kotake et al revealed that ANRIL binds to SUZ12, a Polycomb-group protein of the PRC2 complex, and short hairpin RNA-mediated ANRIL knockdown led to increased p15
INK4b expression, whereas expression of p16 INK4a or p14 ARF was not affected. 91 Taken together, these data suggested that ANRIL might exert its effect by modulating neighboring genes in cis, but results of ANRIL knockdown in the 2 studies are conflicting because different genes were regulated. Nevertheless, both studies showed a significant reduction of cellular proliferation on ANRIL knockdown, a mechanism that is well known to affect atherosclerosis. 91, 92 In contrast to these data, other work in which a transcript of ANRIL was transiently overexpressed in HeLa cells showed that diverse genes were affected in trans. 94 Even though the mechanism of trans regulation has not been investigated in that work, trans regulation of target genes has also been identified for the long noncoding RNA HOTAIR. 95, 96 It will thus be interesting to see whether ANRIL affects gene expression in trans in future studies. Furthermore, the role of circular ANRIL isoforms, identified in the work of Burd et al, 87 needs to be clarified. In summary, even though there is still conflicting evidence about the precise mechanisms, the emerging picture suggests that ANRIL might well constitute a regulator of epigenetic modification and gene expression and thereby modulate cardiovascular risk.
Utility of Chr9p21 for Genetic Risk Prediction
The association of Chr9p21 with cardiovascular disease stimulated a number of studies assessing its potential clinical utility as a genetic risk maker. Most of these studies addressed the question of whether adding Chr9p21 to the currently available models of risk prediction using classical risk factors might improve global risk prediction (Table 2) . Work from the Atherosclerosis Risk in Communities study showed a marginal but statistically significant improvement of C-statistics as well as reclassification. 20 In contrast, earlier work from the Northwick Park Heart Study II only found an improvement of reclassification but not of C-statistics. 23 This is of interest because C-statistics have been criticized for being too rigorous for the evaluation of risk prediction models. In contrast, work from the Women's Health Study 22 and the Cardiovascular Health Study 97 did not show any improvement in reclassification or C-statistics by adding Chr9p21 to conventional risk factors. Thus, current data for the utility of Chr9p21 in risk prediction is unclear, and if there is any added value, it is low. As a perspective, one might envision that adding several genetic markers may result in an improvement of risk prediction. Indeed, simulations have shown that areas under the curve similar to those of conventional CAD risk predictors can be obtained only when a considerable number of additional common genetic variants with preferably strong effects are added. 98 This issue was addressed in a recent combined analysis of the prospective FINRISK and Malmö Diet and Cancer studies 99 using a score of Chr9p21 and 12 additional genetic markers identified in GWASs as of June 2009. However, adding this score to conventional risk factors did not lead to a significant improvement of risk prediction (Table 2) . 99 A possible reason 
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for this result might be that most of the markers used in the genetic score had only very modest effect sizes. 99 Thus, genetic risk prediction may become a reality only when more genetic markers or markers with greater effect sizes are combined. Simulations have shown that a genetic risk profile consisting of 100 markers with ORs in the neighborhood of 1.13 will result in an area under the curve of 0.63. 98 The future will show whether such scores will become feasible.
Summary and Future Directions
Today, Chr9p21 is the most replicated genetic factor of human CAD and other forms of cardiovascular disease such as stroke, peripheral artery disease and arterial aneurysms. In spite of considerable progress, the mechanisms underlying the Chr9p21 effect on atherosclerosis susceptibility are not thoroughly understood. The lack of association of Chr9p21 with common cardiovascular risk factors suggests that it exerts its effect through a completely novel mechanism. Current studies indicate that differential expression of the long noncoding RNA ANRIL, which is transcribed from the Chr9p21 locus, might be a key modulator of cardiovascular risk at the locus. A better understanding of the underlying pathophysiology might provide an opportunity for novel therapeutic options, in particular, because Chr9p21 is independent of classical risk factors and might be used as an additive therapeutic tool.
